MIRMMirum Pharmaceuticals Inc

Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data...

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (12 years of age) with...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on June 10, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,100 shares of common stock and 13,350...

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (FOP) will be presented at ENDO 2026, the...